E Fund Management Co. Ltd. Purchases Shares of 10,238 Emergent BioSolutions Inc. (NYSE:EBS)

E Fund Management Co. Ltd. acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,238 shares of the biopharmaceutical company’s stock, valued at approximately $98,000.

A number of other hedge funds have also modified their holdings of the stock. State Street Corp boosted its position in shares of Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after purchasing an additional 1,713,200 shares during the period. Oak Hill Advisors LP purchased a new position in shares of Emergent BioSolutions in the third quarter worth approximately $9,296,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Emergent BioSolutions in the 4th quarter valued at approximately $1,831,000. Jacobs Levy Equity Management Inc. acquired a new position in Emergent BioSolutions in the 3rd quarter worth approximately $1,547,000. Finally, Wolverine Asset Management LLC purchased a new position in Emergent BioSolutions during the 4th quarter worth approximately $1,303,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $5.77 on Monday. The firm has a market cap of $313.25 million, a price-to-earnings ratio of -1.41 and a beta of 1.80. Emergent BioSolutions Inc. has a 1 year low of $1.82 and a 1 year high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The business has a fifty day simple moving average of $9.33 and a 200 day simple moving average of $8.94.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The business had revenue of $194.70 million during the quarter, compared to analyst estimates of $254.67 million. During the same period in the previous year, the company earned ($0.77) EPS. As a group, sell-side analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EBS has been the subject of a number of research analyst reports. StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, March 4th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.